Neuro-Ophthalmological Manifestations of Obstructive Sleep Apnea: Current Perspectives

This article was published in the following Dove Press journal:
Eye and Brain

Armin Farahvash 1
Jonathan A Micieli 2–4

1Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada; 2Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Ontario, Canada; 3Division of Neurology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada; 4Kensington Vision and Research Centre, Toronto, Ontario, Canada

Abstract: Obstructive sleep apnea (OSA) is a disease of obstructed airways during sleep that significantly impacts the quality of life and increases the risk of various systemic diseases. OSA has been studied as a risk factor for a number of neuro-ophthalmic conditions and a strong relationship has been established with non-arteritic anterior ischemic optic neuropathy (NAION). The incidence of glaucoma and stroke have also been significantly associated with OSA and are conditions that may also be seen by neuro-ophthalmologists. Patients with NAION have a significantly higher incidence of OSA and OSA diagnosis significantly increases the risk for NAION development. Non-compliance with continuous positive airway pressure (CPAP) in OSA patients has also been found to be a risk factor for fellow-eye involvement and there is increasing evidence to suggest that every patient with NAION should be formally evaluated with polysomnography. The relationship between OSA and idiopathic intracranial hypertension (IIH) has also been studied, but the relationship between these two conditions is less clear. There is insufficient evidence to recommend routine eye examinations in OSA patients for papilledema and conducting a sleep study for a newly diagnosed IIH patient should be left to the discretion of the clinician based on other symptoms and risk factors of OSA.

Keywords: ischemic optic neuropathy, non-arteritic anterior ischemic optic neuropathy, idiopathic intracranial hypertension, optic nerve, glaucoma, stroke

Case Vignette
A 63-year-old man with no known medical conditions was seen in neuro-ophthalmology consultation for bilateral vision loss. He noticed blurred vision in his right eye 3 weeks prior to presentation and blurred vision in his left eye 5 days prior to presentation. He denied symptoms suggestive of giant cell arteritis and did not use any medications. He had a visual acuity of 20/400 (right) and 20/60 (left) with a right relative afferent pupillary defect. Humphrey 24–2 SITA-Fast visual fields showed severe generalized depression (right) and an inferior altitudinal defect (left). Dilated fundus examination demonstrated bilateral optic disc edema (Figure 1). Blood pressure was 128/80 mmHg and body mass index was 28.9 kg/m². Review of symptoms was significant for daytime sleepiness, frequent snoring, and witnessed episodes of choking and gasping for air at night by his wife. Informed written and verbal consent was obtained from the patient for inclusion of clinical details and images in this study.

Introduction
Obstructive sleep apnea (OSA) is defined as episodes of upper airway collapse that occur during sleep. These events lead to episodic reduction or cessation of
ventilation, resulting in hypoxia, hypercapnia, or sleep arousal.\(^1\) OSA can significantly impact quality of life and increase the risk of cardiovascular disease, stroke, diabetes, hypertension, and hypercholesterolemia.\(^2\) The incidence of OSA has been estimated to be 3–50% in the general population depending on age, sex, and body mass index (BMI); often, individuals are unaware that they have this condition.\(^3,4\) The incidence of OSA globally does not follow a geographical trend. In men it has been the lowest in Hong Kong (8.8%) and highest in Switzerland (83.8%); while in women, New Zealand and Singapore have the lowest and highest reported rates at 3.4% and 62.3%, respectively.\(^5\)

Conditions that influence the diameter of upper airways during sleep are risk factors of OSA. Obesity and high BMI have been associated with higher degrees of OSA since an increase in the amount of adipose tissue in the tongue or in the upper respiratory pathway can cause airway collapse.\(^2\) Male sex is another major risk factor for OSA with an unclear pathophysiology, although the risk appears to be similar in postmenopausal women.\(^6,7\) It has been hypothesized that progesterones help maintain an appropriate airway diameter and androgens increase pharyngeal muscle mass, increasing the likelihood of airway closure.\(^2,8\) Less established risk factors include smoking, family history of OSA and a variety of medical conditions such as hypertension, type 2 diabetes, congestive heart failure, hypothyroidism, acromegaly, and certain craniofacial anatomical abnormalities.\(^2,9\)

OSA often manifests as daytime sleepiness, snoring, choking or gasping during sleep, and morning headaches. It may also present with complications including erectile dysfunction, neuropsychiatric symptoms, or nocturnal cardiovascular events. However, the correlation of symptoms to the severity of the disease is relatively poor.\(^10\) Currently, the gold standard diagnostic test for OSA is polysomnography to determine the apnea-hypopnea index (AHI).\(^2,10,11\) Apneas are defined as episodes of almost total obstructed airflow of more than 10 seconds during sleep, while hypopneas are decreased airflow and oxyhemoglobin saturation by 3% or arousal from sleep.\(^10\) The AHI score can be used to both diagnose and assess the severity of OSA. An AHI score of 5 or above is indicative of OSA diagnosis. AHI scores of 5–15 are considered mild, 16–30 are considered medium, and above 30 are considered severe OSA.\(^11\) In addition to polysomnography, multiple questionnaires have been developed to assess for OSA that are more accessible and less expensive, including the Berlin questionnaire (BQ), STOP-BANG questionnaire (SBQ), STOP questionnaire (STOP), and Epworth sleepiness scale (ESS). In a meta-analysis of OSA diagnostic questionnaires, SBQ was found to have the highest accuracy and sensitivity compared to the others.\(^12\)

Positive airway pressure such as continuous positive airway pressure (CPAP), which keeps the airways open both during inspiration and expiration while the patient is sleeping, is an effective and commonly used treatment.\(^2,10\) However, patient adherence to CPAP therapy is low due to cost and inconvenience. Weight loss is another effective treatment that has been shown to improve outcomes in patients with OSA. In a meta-analysis of 4 randomized controlled trials, a weight loss of 14 kg was shown to
reduce the AHI score by 16 points. Other treatment options include oral appliance to protract the mandible, avoiding supine sleeping, and surgical intervention to reduce the collapsibility of the pharynx and upper airways.

Neuro-ophthalmology refers to a subspecialty of ophthalmology and neurology that concerns itself with central nervous system pathology affecting vision. An increasing amount of evidence has implicated OSA as a significant risk factor for optic nerve disorders (referred to as optic neuropathies). These include non-arteritic anterior ischemic optic neuropathy (NAION) and to a lesser extent idiopathic intracranial hypertension (IIH). This review will examine the evidence for OSA as a risk factor for neuro-ophthalmological conditions with a focus on NAION and IIH.

**OSA and NAION**

Non-arteritic anterior ischemic optic neuropathy (NAION) occurs due to infarction of the optic nerve head due to hypoperfusion of the short posterior ciliary arteries. This condition manifests as painless vision loss and the optic nerve becomes edematous after the initial insult and the optic disc edema persists for about 6–11 weeks after which optic disc atrophy develops. It is seen in patients with small optic nerves and a small or absent physiological cup (so-called “disc-at-risk”). NAION commonly affects individuals above the age of 50 and is associated with vascular risk factors such as hypertension and type 2 diabetes. Other associated risk factors include dyslipidemia, smoking, and systemic atherosclerosis, but few rigorous population studies exist to establish these factors. We used a systematic search strategy (Table 1) and identified 18 articles that have explored the association between OSA and NAION (Table 2).

The relationship between OSA and optic disc edema was first described by Bucci et al in a 46-year-old obese male with OSA. This patient had an extensive workup including a lumbar puncture that revealed a normal opening pressure and following the placement of a permanent tracheotomy for the treatment of his OSA symptoms, his optic disc edema resolved. This observation encouraged Mojon et al to systematically investigate the association between OSA and NAION for the first time. They examined the frequency of OSA by polysomnograms in patients with NAION and compared it to age- and sex-matched controls who had restless leg syndrome. They showed that NAION patients had significantly higher rates of OSA diagnosis at 71% compared to the controls at 18%.

Another study conducted phone questionnaires of 73 NAION patients and 73 age- and gender-matched controls, and assessed the OSA status of the participants based on the Sleep Apnea scale of the Sleep Disorders Questionnaire (SA-SQD). Even though they used a different, indirect method of assessing for OSA, they found higher rates of OSA in NAION patients than the controls, 30.1% versus 17.8%, consistent with other studies.

Unlike other prospective studies that matched the control group based only on age and sex, two studies matched them based on the diagnoses of diabetes and hypertension as well. The results were consistent in finding that the rate of OSA was 85% (17/20 patients) and 55.5% (15/27 patients) in NAION patients, which was significantly higher than the controls at 65% (13/20) and 22.2% (6/27), respectively. These studies demonstrated that even after controlling for all major risk factors of NAION including age, diabetes, and hypertension, OSA still appears to be strongly associated with NAION.

Conversely, other studies have investigated the frequency of NAION in patients with OSA. Comparative retrospective studies of OSA patients versus controls have shown higher incidences of NAION diagnosis in OSA patients at 0.92% and 0.36% compared to the controls at 0.42% and 0.20%, respectively. In addition, after adjustments for comorbidities, OSA patients had

| Table 1 Search Strategy Used for OVID MEDLINE (1946 to February 2020 Week 1) to Identify Studies That Investigated the Relationship Between OSA and NAION |
|---|---|
| # | Searches | Results |
| 1 | exp Optic Neuropath, Ischemic/ | 1620 |
| 2 | Optic Nerve Diseases/ | 8819 |
| 3 | Non-arteritic anterior ischemic optic neuropathy.tw. | 181 |
| 4 | Nonarteritic anterior ischemic optic neuropathy.tw. | 435 |
| 5 | NAION.tw. | 487 |
| 6 | Arteritic anterior ischemic optic neuropathy.tw. | 235 |
| 7 | exp Sleep Apnea, Obstructive/ | 20,406 |
| 8 | Obstructive sleep apnea.tw. | 22,456 |
| 9 | Obstruct* Sleep Apnea*.tw. | 22,522 |
| 10 | Sleep apnea syndrome.tw. | 6738 |
| 11 | OSA.tw. | 13,639 |
| 12 | 1 or 2 or 3 or 4 or 5 or 6 or 7 | 10,601 |
| 13 | 8 or 9 or 10 or 11 or 12 | 32,996 |
| 14 | 12 and 13 | 55 |
| 15 | limit 14 to (English language and humans) | 50 |
| Authors, Year | Number of Patients | Type of Study | OSA Diagnostic Test | Findings |
|--------------|--------------------|---------------|---------------------|----------|
| Mojon et al<sup>16</sup> 2002 | 17 NAION patients and 17 age- and sex-matched controls | Prospective comparative | PSG | 12/17 (71%) of NAION and 3/17 (18%) of controls had OSA |
| Behbehani et al<sup>17</sup> 2004 | 108 patients with OSA | Prospective observational | PSG | 3/108 (2.78%) of the patients had NAION |
| Palombi et al<sup>18</sup> 2006 | 27 NAION patients | Prospective observational | PSG | 24/27 (89%) of the patients had OSA |
| Li et al<sup>19</sup> 2007 | 73 NAION patients and 73 age- and gender-matched controls | Prospective comparative | SA-SDQ | OSA diagnosis based on a phone questionnaire 22/73 (30.1%) of NAION patients and 13/73 (17.8%) of the controls had OSA |
| Stein et al<sup>20</sup> 2011 | 2,259,061 patients, 156,336 of whom diagnosed with OSA | Retrospective comparative | Medical history | OSA patients who did not use CPAP had an NAION diagnosis rate of 0.07% as opposed to 0.05% in the controls |
| Arda et al<sup>21</sup> 2012 | 20 NAION patients and 20 age- and sex-matched controls with similar rate of hypertension and diabetes | Prospective comparative | PSG | 17/20 (85%) of the NAION patients and 13/20 (65%) of the controls had OSA |
| Blaivas et al<sup>22</sup> 2013 | 1 | Case report | PSG | Patient with bilateral NAION was found to be having underlying OSA due to a subternal goiter |
| Kolb et al<sup>23</sup> 2013 | 17 NAION patients | Prospective observational | PSG | 11/17 (64.7%) of the NAION had OSA |
| Bilgin et al<sup>24</sup> 2013 | 27 NAION patients and 27 age- and sex-matched controls and similar systemic risk factors | Prospective comparative | PSG | 15/27 (55.5%) of the NAION patients and 6/27 (22.2%) of the controls had OSA |
| Mohamed et al<sup>25</sup> 2014 | 30 OSA patients | Prospective observational | PSG | 4/30 (13.33%) OSA patients had NAION |
| Lacharme et al<sup>26</sup> 2014 | 17 NAION patients | Prospective observational | PSG | 12/17 (70.6%) of the patients had OSA |
| Aptel et al<sup>27</sup> 2015 | 89 NAION patients | Prospective observational | PSG | 67/89 (75%) of the patients had OSA. |
| Ghaeleh Bandi et al<sup>28</sup> 2015 | 19 NAION patients and 31 controls | Prospective comparative | PSG | 18/19 (95%) of NAION and 13/31 (41.9%) of controls had OSA |
| Morsi et al<sup>29</sup> 2019 | 80 OSA patients and 20 controls | Retrospective | PSG | No patient had NAION |
| Sun et al<sup>30</sup> 2019 | 8488 OSA patients and 33,952 controls | Retrospective | Medical history | Rate of NAION diagnosis was 0.36% in the OSA group and 0.2% in the controls |
| Yang et al<sup>31</sup> 2018 | 919 with OSA, 9190 matched non-OSA | Retrospective | Medical history | 10-year incidence probability of NAION in the OSA group (0.92%) was higher than the non-OSA group (0.42%) |
| Chang et al<sup>32</sup> 2019 | 119 patients with unilateral NAION | Retrospective | Medical history | Over a 5-year period, 24.4% of the patients developed NAION in the other eye, with CPAP non-compliance being a major risk factor |
| Lei et al<sup>33</sup> 2019 | 1 | Case report | PSG | Young patient with NAION who had undiagnosed severe OSA |

**Abbreviations:** OSA, obstructive sleep apnea; NAION, non-arteritic anterior ischemic optic nerve; PSG, polysomnogram; SA-SDQ, Sleep Apnea scale of the Sleep Disorders Questionnaire; CPAP, continuous positive air pressure.
a significantly higher risk of developing NAION than patients without OSA over an 18-year period, with a reported hazard ratio of 1.66. Thus, OSA appears to be highly prevalent among NAION patients while NAION is much less common among OSA patients. This is likely a result of the multifactorial nature of NAION including the importance of a disc-at-risk. In addition, since OSA is consistently more prevalent in patients with NAION compared to controls, it suggests that OSA is a risk factor for NAION development.

A meta-analysis of 4 case-control studies, involving 137 subjects showed that OSA was significantly associated with the development of NAION with a pooled odds ratio of 3.126 (P<0.001) in the OSA group.

Likewise, another meta-analysis of 5 studies, found a strong link between NAION and OSA with a pooled odds ratio of 6.18 (95% CI 2.00–19.11) versus non-OSA controls. In subgroup analysis, only matched-control studies showed a significant association between NAION and OSA with an odds ratio of 5.0 (95% CI 2.22–11.25), compared to studies that did not. This difference could be explained by the fact that NAION is a multifactorial disease.

A few studies have also reported the potential for CPAP therapy to minimize the risk of developing NAION in patients with OSA. Chang et al retrospectively studied 119 patients with unilateral NAION and OSA. Over a 5-year period, 29 of these patients developed NAION in the other eye as well. They found that poor adherence to CPAP was a major risk factor in developing bilateral NAION. This emphasizes the importance of treating OSA when present to prevent fellow-eye involvement, which often has a tremendous impact on their quality of life.

The exact mechanism of how OSA causes NAION is not fully understood but various hypotheses have been proposed. Many studies in the literature suggest that recurrent episodes of apnea lead to vascular dysregulation, compromising the ability to provide constant blood flow to the vessels supplying the optic nerve head. This dysregulation has been thought to be a result of prolonged hypoxia, production of reactive oxygen species, and an imbalance in the production of vasoactive substances. Vascular endothelial growth factor (VEGF) has been reported to stimulate the progression of cardiovascular disease and a meta-analyses of six studies found that levels of VEGF were significantly reduced in OSA after CPAP treatment.

Given the strong association between OSA and NAION, there is increasing evidence that polysomnography should be performed in all patients with a new diagnosis of NAION. This is important since there is evidence, as outlined above, that CPAP non-compliance is a risk factor for developing bilateral NAION. OSA should be of particular concern in patients that have a clear diagnosis of NAION, but no other risk factors for this condition. OSA is also a concern in younger patients below 50 years of age and NAION has been found to be the presenting condition of severe sleep apnea in younger individuals. Although there is no established treatment for NAION, efforts should be focused on identification and optimization of risk factors including OSA to reduce the likelihood of fellow-eye involvement, which can be devastating for these patients.

**OSA and IIH**

Idiopathic intracranial hypertension (IIH), also known as pseudotumor cerebri, refers to increased intracranial pressure (ICP) of unknown cause. It is most commonly seen in obese females of childbearing age and may present with headache, diplopia, or vision loss. IIH is diagnosed by the modified Dandy criteria and treatment is initiated to reduce the risk of permanent vision loss and help in reducing systemic symptoms. These treatments include weight loss, pharmacological treatments such as acetazolamide, or surgical intervention in severe cases. Studies have shown that in patients with OSA, ICP was relatively normal during wake times with morning ICP values significantly higher than the evening values (20.7 mmHg versus 17.7, p=0.02). However, this value was increased as much as 90 mmHg during apnea episodes. This correlation was highly significant and was associated with a decrease in PO2. Since IIH is a syndrome of raised ICP, this sparks the question of a potential relationship between IIH and OSA. Table 3 summarizes the 19 articles that have explored the association between OSA and IIH (Table 3). OSA has been reported to occur between 4% and 60% of IHH patients. Many cases have been described in the literature describing patients with OSA who were also diagnosed with IIH at presentation, proposing a possible link between the two conditions. However, unlike NAION, the evidence for an association between IIH and OSA is less conclusive.

Thurtell et al conducted polysomnograms on 24 patients with a diagnosis of IIH and found that 8 of these patients had OSA. The mean AHI score of these individuals was compared to a model developed by sampling the AHI scores of 1741 random individual and corrected for age, sex, race, BMI, and menopausal status. The results
| Authors, Year       | Number of Patients | Type of Study | OSA Diagnostic Test | Findings                                                                 |
|--------------------|-------------------|---------------|---------------------|---------------------------------------------------------------------------|
| Doyle et al\(^{12}\) 1991 | 1                 | Case report   | Medical history     | Obese patient with OSA and IIH presenting with unilateral vision loss who improved following a lumboperitoneal shunt and tracheotomy |
| Purvin et al\(^{43}\) 2000 | 1                 | Case report   | Medical history     | Obese patient with a 2-year history of OSA presenting with unilateral vision loss, papilledema and high ICP during sleep |
| Marcus et al\(^{44}\) 2001 | 14 IIH patients with symptoms of sleep disturbance | Retrospective  | PSG                 | 6/14 (42.9%) of the patients had OSA                                      |
| Lee et al\(^{45}\) 2001 | 18 men with IIH   | Retrospective  | Medical history     | 6/18 (33.3%) of the patients had OSA                                      |
| Thambisetty et al\(^{46}\) 2006 | 16 fulminant IIH female patients | Prospective observational | Medical history | None of the patients had OSA                                            |
| Bruce et al\(^{47}\) 2009 | 721 IIH patients | Retrospective  | Medical history     | 25/655 (4%) of the female patients had OSA as opposed to 16/66 (24%) of the male patients |
| Fraser et al\(^{48}\) 2010 | 24 IIH male patients and 48 sex-, age-, race-, and BMI category-matched controls | Prospective comparative | Berlin Questionnaire (BQ) for OSA | Following adjustments for BMI, IIH patients had a higher likelihood of having a positive Berlin questionnaire or history of OSA diagnosis |
| Thurtell et al\(^{49}\) 2011 | 30 newly-diagnosed IIH patients | Prospective | PSG and BQ          | PSG: 18/30 (60%) of the patients had OSA BQ: 20/30 (67.8%) of patients were at high risk of OSA |
| Javaheri et al\(^{50}\) 2011 | 1                 | Case report   | PSG                 | Female patient with IIH who was diagnosed with OSA. Her IIH improved following CPAP therapy for OSA |
| Stein et al\(^{51}\) 2011 | 2,259,061 patients, 156,336 of whom diagnosed with OSA | Retrospective | Medical history     | OSA patients who did not use CPAP had an IIH diagnosis rate of 0.04% as opposed to 0.01% in the controls |
| Szewka et al\(^{52}\) 2013 | 414 IIH patients | Retrospective  | Medical history     | In patients with BMI of <40, 13/256 (5.1%) had OSA as opposed to 26/158 (16.5%) in patients with BMI >4 |
| Abraham et al\(^{53}\) 2013 | 22 IIH and 12 sex- and age-matched controls | Prospective comparative | Bedside overnight respiratory monitoring | AHI scores of IIH patients higher than the control, but both values within the normal range |
| Thurtell et al\(^{53}\) 2013 | 24 IIH patients | Prospective observational | PSG                 | 8/24 (33.3%) of IIH patients had OSA. The AHI scores of the IIH patients and 1741 randomly sampled individuals had no statistical difference |
| Wardly et al\(^{54}\) 2017 | 1                 | Case report   | PSG                 | Patient with OSA and IIH. Her IIH went away following a clockwise maxillomandibular advancement surgery to treat OSAS |
| Cappuzzo et al\(^{55}\) 2018 | 18 IIH patients  | Retrospective  | Medical history     | 3/18 (16.7) of IIH patients had OSA                                     |

(Continued)
showed that there was no difference between the AHI scores of the two groups, indicating that IIH by itself did not increase the risk of developing OSA. In another study, Bruce et al surveyed 721 patients with IIH and found that 5.7% of these patients also had OSA. In addition, when they looked at the rate of OSA between sexes they found that males had a higher rate at 24% compared to females at 4%. In a study focused on racial differences in IIH, it was found that black individuals had a higher proportion of OSA (9% vs 4%; p=0.01) and that OSA was more likely in patients that had severe visual loss (p=0.002).

A few studies have found lower rates of OSA in patients with IIH compared to the controls. In a large retrospective study, Ardissino et al found that among 607 IIH patients, only 4 of them (0.7%) had OSA. Conversely, 2204 of the 230,792 controls (1%) had an OSA diagnosis. Chronic IIH and increased ICP have also been shown to contribute to the development of spontaneous cerebrospinal fluid leaks (sCSF-L). sCSF-L has been associated with thinning of the calvarium with no changes to extracranial bones and is linked with obesity and OSA. In particular, the incidence of OSA in sCSF-L patients was reported to be 83.3% and patients with OSA have been shown to have a thinner mean calvaria. This suggests that there might be an indirect link between OSA and chronic untreated IIH.

Overall, there is little evidence for increased ICP in patients with OSA and fundus examination screening for papilledema in OSA patients is not warranted at this time. A few studies demonstrated a potential link between IIH and OSA, but these were small and without comparative groups. There is therefore no strong evidence supporting routine testing for OSA in patients with IIH. However, weight loss has been shown to be an effective treatment for both IIH and is also an important treatment modality in patients with OSA.

### OSA and Glaucoma

Glaucoma is a multifactorial collection of eye diseases that is characterized by degeneration of retinal ganglion cells leading to a progressive optic neuropathy and is associated with cupping of the optic disc and increased intraocular pressure. The incidence of glaucoma in patients with OSA has been reported to be anywhere between 2% and 27%. While some studies have found the rate of glaucoma to be the same between OSA patients and the general population, others have described a higher incidence in OSA patients.

In a study of 69 OSA patients and 45 controls undergoing a sleep study, none of the patients in the control group had glaucoma while 7.2% of the OSA patients did, of which 40% had normal-tension glaucoma and 60% had primary open-angle glaucoma. Glaucoma incidence of 7.2% in the OSA patients was also significantly higher than the 2% rate in the general population (p<0.001).

A meta-analysis of 12 studies has shown an overall increased risk of glaucoma development in patients with OSA with an odds ratio of 1.65 (CI, 1.44–1.88). Subgroup analysis revealed that this significant increase was only observed in patients with primary open-angle glaucoma but not in normal-tension glaucoma. In addition, patients with severe OSA had an even more significant
increased odds (OR: 5.49) of developing glaucoma compared to patients with mild or moderate OSA. 69

The risk of glaucoma development in 1012 OSA patients and 6072 healthy controls was investigated over 5 years. 70 The incidence of glaucoma was 11.26% in patients with OSA compared to 6.76% in the controls. Even after adjustment for demographics and risk factors, OSA patients were 1.67 times more likely to develop glaucoma (95% CI, 1.30, 2.17; P<0.001). 70

In addition to be correlated with a higher incidence of glaucoma development, OSA has been found to influence the anatomical progression of disease in glaucoma. In a cohort study of 32 patients, those with moderate and severe OSA had a statistically higher degree of retinal nerve fiber layer thinning than patients with no or mild OSA. 71 In addition, severe OSA had an increased risk of retinal nerve fiber layer thinning by a factor of 8.448 (95% CI, 1.464–48.752; P<0.017). 71

Overall, the evidence suggests that patients with OSA have an increased risk of developing glaucoma. This progressive ischemia of the optic nerve could be due to chronic hypoperfusion of the optic nerve head during the apnea episodes or dysregulation of vascular modulating cytokines as a result of OSA. Investigation with polysomnography can therefore be considered in patients with glaucoma, especially if there is progression despite the achievement of target intraocular pressure.

**OSA and Stroke**

Stroke affecting the retrochiasmal visual pathways is a leading cause of homonymous visual field defects and OSA has been established as a risk factor for stroke. The study by Dyken et al was one of the first studies that showed a higher incidence of OSA in patients with a recent episode of ischemic or hemorrhagic stroke. 72 They conducted polysomnograms and found that 70.8% of the 24 recent stroke patients had OSA as opposed to 18.5% of the 27 age- and sex-matched controls. Furthermore, 54% of the patients experienced stroke during sleep, suggesting that the apnea episodes of OSA might be a cause. 72

Artz et al conducted a study with a retrospective cross-sectional part of 1475 patients and a prospective 4-year longitudinal part that included 1189 patients who did not have a history of stroke. 73 The cross-sectional study revealed that patients with an AHI score of 20 or higher have an increased odds of developing stroke with an OR of 4.33 (CI: 1.32–14.24) after adjustment for known confounding factors. Additionally, the longitudinal study showed that patients with an AHI score above 20 have a higher risk of first-time stroke occurrence over 4 years (OR 3.08, CI: 0.74–12.81). 73

In another longitudinal study, a cohort of 394 non-hospitalized elderly (70 or older) subjects with no history of stroke were followed for 6 years. 74 Twenty patients experienced stroke in the duration of the study, with an average AHI score of 28 as opposed to 20.1 in individuals who did not have a stroke. Moreover, after adjustment for confounding variables, subjects with severe OSA (AHI>30) were found to have an increased risk of stroke (HR 2.52, CI 1.04–6.01). 74 Overall, this study demonstrated that even in older patients, OSA diagnosis is associated with a higher risk of stroke occurrence. Over a 20-year period, Marshall et al recorded 31 strokes in 393 patients who were assessed for OSA using a portable home-monitoring device. 75 They found that moderate-severe OSA was associated with stroke with an HR of 3.7 (CI: 1.2–11.8). 75

Overall, various observational and longitudinal studies have demonstrated a strong association between OSA and stroke, such that the more severe OSA leads to a higher risk of stroke occurrence. This may have an impact on vision since stroke is a leading cause of homonymous visual field defects.

**Conclusion**

The strongest association with obstructive sleep apnea in the area of neuro-ophthalmology is with NAION. Multiple prospective studies and meta-analyses have demonstrated an increased risk of this condition in patients with NAION. There is increasing evidence that polysomnography should be strongly considered in all patients with NAION and treatment with CPAP is recommended to reduce the risk of fellow-eye involvement. There is a much weaker relationship between IIH and OSA and there is insufficient evidence to recommend routine polysomnography in this patient population at this time. Patients with homonymous visual field defects are commonly diagnosed with stroke and it is important to recognize that there is an association between stroke and OSA, which may also be the first manifestation of undiagnosed OSA.

**Return to Case Vignette**

The patient was diagnosed with bilateral NAION after giant cell arteritis was excluded and magnetic resonance of the brain and orbits with contrast was normal. Given the concerning symptoms for OSA, he underwent
polysomnography, which revealed severe OSA with an AHI of 48.4 per hour. He was treated with CPAP and worked on lifestyle modifications to help with weight loss. His visual function was mildly improved to 20/80 (right) and 20/40 (left) at the 6-month follow-up.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**

1. Dempsey JA, Veasey SC, Morgan BJ, O’Donnell CP. Pathophysiology of sleep apnea. *Physiol Rev.* 2010;90(1):47–112. doi:10.1152/physrev.00043.2008
2. Veasey SC, Rosen IM, Solomon CG. Obstructive sleep apnea in adults. *N Engl J Med.* 2019;380(15):1442–1449. doi:10.1056/NEJMcp1811652
3. Peppard PE, Young T, Barnet JH, Palta M, Hagen EW, Hla KM. Increased prevalence of sleep-disordered breathing in adults. *Am J Epidemiol.* 2013;177(9):1006–1014. doi:10.1093/aje/kws342
4. Heinzner R, Vat S, Marques-Vidal P, et al. Prevalence of sleep-disordered breathing in the general population: the HypnoLaus study. *Lancet Respir Med.* 2015;3(4):310–318. doi:10.1016/S2213-2600(15)00043-0
5. Benj affiliated AV, Ayas NT, Eastwood PR, et al. Estimation of the Global prevalence and burden of obstructive sleep apnea: a literature-based analysis. *Lancet Respir Med.* 2019;7(8):687–698. doi:10.1016/S2213-2600(19)30198-5
6. Young T, Finn L, Austin D, Peterson A. Menopausal status and sleep-disordered breathing in the Wisconsin sleep cohort study. *Am J Respir Crit Care Med.* 2003;167(9):1181. doi:10.1164/rccm.200209-1055OC
7. Quintana-Gallego E, Carmona-Bernal C, Capote F, et al. Gender differences in obstructive sleep apnea syndrome: a clinical study of 1166 patients. *Respir Med.* 2004;98(10):984–989. doi:10.1016/j.rmed.2004.03.002
8. Liu PY, Yee B, Wishart SM, et al. The short-term effects of high-dose testosterone on sleep, breathing, and function in older men. *J Clin Endocrinol Metab.* 2003;88(8):3605–3613. doi:10.1210/jc.2003-030236
9. Ozcan KM, Selecuk A, Ozcan I, et al. Incidence of hypothyroidism and its correlation with polysomnography findings in obstructive sleep apnea. *Eur Arch Otorhinolaryngol.* 2014;271(11):2937–2941. doi:10.1007/s00405-014-2962-1
10. Laratta CR, Ayas NT, Povitz M, Pendharkar SR. Diagnosis and treatment of obstructive sleep apnea in adults. *CMAJ.* 2017;189(48):E1481–E1488. doi:10.1503/cmaj.170296
11. Ruehlend WR, Rochford PD, O’Donoghue FJ, Pierce RJ, Singh P, Thornton AT. The new AASM criteria for scoring hypopneas: impact on the apnea hypopnea index. *Sleeep.* 2009;32(2):150–157. doi:10.1093/sleep/32.2.150
12. Chiu HY, Chen PY, Chuang LP, et al. Diagnostic accuracy of the Berlin questionnaire, STOP-BANG, STOP, and Epworth sleepiness scale in detecting obstructive sleep apnea: a bivariate meta-analysis. *Sleep Med Rev.* 2017;36:57–70. doi:10.1016/j.smvr.2016.10.004
13. Mitchell LJ, Davidson ZE, Bonham M, O’Driscoll DM, Hamilton GS, Truby H. Weight loss from lifestyle interventions and severity of sleep apnoea: a systematic review and meta-analysis. *Sleep Med.* 2014;15(10):1173–1183. doi:10.1016/j.sleep.2014.05.012
14. Biosse V, Newman NJ. Ischemic optic neuropathies. *N Engl J Med.* 2015;373(24):2390.
15. Peeler C, Cestari DM. Non-arteritic anterior ischemic optic neuropathy (NAION): a review and update on animal models. *Semin Ophthalmol.* 2016;31(3):99–106. doi:10.1179/08820538.2015.1115248
16. Mojon DS, Hedges TR, Ehrenberg B, et al. Association between sleep apnea syndrome and nonarteritic anterior ischemic optic neuropathy. *Arch Ophthalmol.* 2002;120(5):601–605. doi:10.1001/archoph.120.5.601
17. Behbehani R, Mathews MK, Sergott RC, Savino PJ. Nonarteritic anterior ischemic optic neuropathy in patients with sleep apnea while being treated with continuous positive airway pressure. *Am J Ophthalmol.* 2005;139(3):518–521. doi:10.1016/j.ajo.2004.11.004
18. Palombi F, Renard E, Levy P, et al. Non-arteritic anterior ischemic optic neuropathy is nearly systematically associated with obstructive sleep apnea. *Br J Ophthalmol.* 2006;90(7):879–882. doi:10.1136/bjo.2005.087452
19. Li J, McGwin G, Vaphiades MS, Owsey C. Non-arteritic anterior ischemic optic neuropathy and presumed sleep apnoea syndrome screened by the sleep apnea scale of the sleep disorders questionnaire (SA-SDQ). *Br J Ophthalmol.* 2007;91(11):1524–1527. doi:10.1136/bjo.2006.113803
20. Stein JD, Kim DS, Mundy KM, et al. The association between glaucomatous and other causes of optic neuropathy and sleep apnea. *Am J Ophthalmol.* 2011;152(6):989–998.e3. doi:10.1016/j.ajo.2011.04.030
21. Arda H, Birer S, Aksu M, et al. Obstructive sleep apnoea prevalence in non-arteritic anterior ischemic optic neuropathy. *Br J Ophthalmol.* 2013;97(2):206–209. doi:10.1136/bjoophthal-2012-302598
22. Blaivas AJ, Uddin F. Obstructive sleep apnea caused by substernal goiter presenting as nonarteritic ischemic optic neuropathy. *Sleep Breath.* 2013;17(2):469–471. doi:10.1007/s11325-012-0758-3
23. Kolb SD, Backhouse O. Obstructive sleep apnea prevalence in non-arteritic anterior ischemic optic neuropathy: a response. *Br J Ophthalmol.* 2013;97(6):794. doi:10.1136/bjophthalmol-2013-303179
24. Bilgin G, Koban Y, Arnold AC. Nonarteritic anterior ischemic optic neuropathy and obstructive sleep apnea. *J Neuroophthalmol.* 2012;33(3):232–234. doi:10.1097/WNO.0b013e31822e8eebd
25. Mohamed EE, Massoud TH. Effect of sleep related breathing disorders on ocular function. *Egypt J Chest Dis Tuberc.* 2014;63(3):663–669. doi:10.1016/j.ejcdt.2014.02.010
26. Lacharme T, Almanjoumi A, Aptel F, et al. Twenty-four-hour rhythm of ocular perfusion pressure in non-arteritic anterior ischemic optic neuropathy. *Acta Ophthalmol.* 2014;92(5):e346–52. doi:10.1111/aos.12352
27. Aptel F, Khayi H, Pépin JL, et al. Association of nonarteritic ischemic optic neuropathy with obstructive sleep apnea syndrome: consequences for obstructive sleep apnea screening and treatment. *JAMA Ophthalmol.* 2015;133(7):797–804. doi:10.1001/jamaophthalmol.2015.10893
28. Ghaleh Bandi MF, Naserbakht M, Tabasi A, Marghaizadeh A, Riazez Espahani M, Golzarian Z. Obstructive sleep apnea syndrome and non-arteritic anterior ischemic optic neuropathy: a case control study. *Med J Islam Repub Iran.* 2015;29:300.
29. Morsy NE, Amani BE, Magda AA, et al. Prevalence and predictors of ocular complications in obstructive sleep apnea patients: a cross-sectional case-control study. *Open Respir Med J.* 2019;13(1):19–30. doi:10.2174/18743604196310130019
20. Sun MH, Lee CY, Liao YJ, Sun CC. Nonarteritic anterior ischemic optic neuropathy and its association with obstructive sleep apnoea: a health insurance database study. *Acta Ophthalmol.* 2019;107(1):e64–e70. doi:10.1111/aos.13832
31. Yang HK, Park SJ, Byun SJ, Park KH, Kim JW, Hwang JM. Obstructive sleep apnoea and increased risk of non-arteritic anterior ischemic optic neuropathy. *Br J Ophthalmol.* 2019;103(8):1123–1128. doi:10.1136/bjophthalmol-2018-312910
32. Chang MY, Keltner JL. Risk factors for fellow eye involvement in nonarteritic anterior ischemic optic neuropathy. J Neuroophthalmol. 2019;39(2):147–152. doi:10.1097/WNO.0000000000000715
33. Lei S, Micieli JA. Severe obstructive sleep apnea diagnosed after nonarteritic anterior ischaemic optic neuropathy in a young man. BMJ Case Rep. 2019;12(11):pii:e22512. doi:10.1136/bcr-2019-232512
34. Bucci FA, Krohel GB. Optic nerve swelling secondary to the obstructive sleep apnea syndrome. Am J Ophthalmol. 1998;105(4):426–430. doi:10.1016/S0002-9394(98)90318-2
35. Huon LK, Liu SY, Camacho M, Guilleminault C. The association between ophthalmologic diseases and obstructive sleep apnea: a systematic review and meta-analysis. Sleep Breath. 2016;20(4):1145–1150. doi:10.1007/s11325-016-1358-4
36. Wu Y, Zhou LM, Lou H, Cheng JW, Wei RL. The association between obstructive sleep apnea and nonarteritic anterior ischemic optic neuropathy: a systematic review and meta-analysis. Curr Eye Res. 2016;41(7):987–992. doi:10.1016/j.cert.2015.1075221
37. Hayreh SS. The optic nerve head circulation in health and disease. Exp Eye Res. 1995;61(3):259–272. doi:10.1006/excr.1995.0041
38. Qi JC, Zhang L, Li H, et al. Impact of continuous positive airway pressure on vascular endothelial growth factor in patients with obstructive sleep apnea: a meta-analysis. Sleep Breath. 2019;23(1):5–12. doi:10.1007/s11325-018-1660-4
39. Mentek M, Aptel F, Godin-Ribout D, Tamisier R, Pepin JL, Chiquet C. Diseases of the retina and the optic nerve associated with obstructive sleep apnea. Sleep Med Rev. 2018;38:113–130. doi:10.1016/j.smrv.2017.05.003
40. Madriz Peralta G, Cestari DM. An update of idiopathic intracranial hypertension. Curr Opin Ophthalmol. 2018;29(6):495–502. doi:10.1097/ICO.0000000000000518
41. Wall M. Update on idiopathic intracranial hypertension. Neurol Clin. 2017;35(1):45–57. doi:10.1016/j.ncl.2016.08.004
42. Doyle KJ, Tami TA. Increased intracranial pressure and blindness associated with obstructive sleep apnea. Otolaryngol Head Neck Surg. 1991;105(4):613–616. doi:10.1016/0194-5998(91)90504-13
43. Purvin VA, Kawasaki A, Yee RD. Papilledema and obstructive sleep apnea syndrome. Arch Ophthalmol. 2000;118(12):1626–1630. doi:10.1001/archopht.118.12.1626
44. Marcus DM, Lynn J, Miller JJ, Chaudhary O, Thomas D, Chaudhary B. Sleep disorders: a risk factor for pseudotumor cerebri? J Neuroophthalmol. 2001;21(2):121–123. doi:10.1097/00004137-200106000-00014
45. Lee AG, Golnik K, Kardon R, Wall M, Eggenberger E, Vedavally S. Sleep apnea and intracranial hypertension in men. Ophthalmology. 2002;109(3):482–485. doi:10.1016/S0161-6420(01)00987-3
46. Thambisetty M, Lavin PJ, Newman NJ, Bioussé V. Fulminant idiopathic intracranial hypertension. Neurology. 2007;68(3):229–232. doi:10.1212/01.wnl.0000253122.19452.ec
47. Bruce BB, Kedar S, Van Stavern GP, et al. Idiopathic intracranial hypertension in men. Neurology. 2009;72(4):304–309. doi:10.1212/01.wnl.0000332524.84120.f5
48. Fraser JA, Bruce BB, Rucker J, et al. Risk factors for idiopathic intracranial hypertension in men: a case-control study. J Neurol Sci. 2010;290(1–2):86–89. doi:10.1016/j.jns.2009.11.001
49. Thurtell MJ, Bruce BB, Rye DB, Newman NJ, Bioussé V. The Berlin questionnaire screens for obstructive sleep apnea in idiopathic intracranial hypertension. J Neuroophthalmol. 2011;31(4):316–319. doi:10.1097/WNO.0b013e31841d454
50. Javaheri S, Qureshi Z, Golnik K. Resolution of papilledema associated with OSA treatment. J Clin Sleep Med. 2011;7(4):399–400. doi:10.5664/JCSM.1202
51. Szewka AJ, Bruce BB, Newman NJ, Bioussé V. Idiopathic intracranial hypertension: relation between obesity and visual outcomes. J Neuroophthalmol. 2013;33(1):4–8. doi:10.1097/WNO.0b013e31823b852d
52. Abraham A, Peled N, Khllekovska A, et al. Nocturnal carbon dioxide monitoring in patients with idiopathic intracranial hypertension. Clin Neurol Neurosurg. 2013;115(8):1379–1381. doi:10.1016/j.clineuro.2012.12.037
53. Thurtell MJ, Torti LM, Bixler EO, et al. Obstructive sleep apnea in idiopathic intracranial hypertension: comparison with matched population data. J Neurol. 2013;260(7):1748–1751. doi:10.1007/s00415-013-6858-6
54. Wardy D, Wolford LM, Veerappan V. Idiopathic intracranial hypertension eliminated by counterclockwise maxillomandibular advancement: a case report. Otolaryngol Head Neck Surg. 2017;156(5):1096–1101. doi:10.1177/0161327616658906
55. Radojicic A, Vukovic-Cvetkovic V, Pekmezovic T, Trajkovic G, Zivedic-Trajkovic J, Hansen RH. Predictive role of presenting symptoms and clinical findings in idiopathic intracranial hypertension. J Neurol Sci. 2019;399:89–93. doi:10.1016/j.jns.2019.02.006
56. Onder H, Ergun O, Kaygizis M, Daltaban IS. Total improvement after surgery for obstructive sleep apnea syndrome in a patient with concurrent malignant idiopathic intracranial hypertension. J Neurol Surg. 2018;79(2):582–586. doi:10.1016/j.jns.2017.08.011
57. Rabbani C, Saltagi MZ, Ye MJ, et al. Association of obstructive sleep apnea with calvarial and skull base thinning. BMJ Case Rep. 2019;12(11): pii: e232512. doi:10.1136/bcr-2019-232512
58. Farahvash and Micieli 51. Szewka AJ, Bruce BB, Newman NJ, Bioussé V. Idiopathic intracranial hypertension: relation between obesity and visual outcomes. J Neuroophthalmol. 2013;33(1):4–8. doi:10.1097/WNO.0b013e31823b852d
70. Lin CC, Hu CC, Ho JD, Chiu HW, Lin HC. Obstructive sleep apnea and increased risk of glaucoma: a population-based matched-cohort study. *Ophthalmology*. 2013;120(8):1559–1564. doi:10.1016/j.ophtha.2013.01.006
71. Fan YY, Su WW, Liu CH, et al. Correlation between structural progression in glaucoma and obstructive sleep apnea. *Eye*. 2019;33(9):1459–1465. doi:10.1038/s41433-019-0430-2
72. Dyken ME, Somers VK, Yamada T, Ren ZY, Zimmerman MB. Investigating the relationship between stroke and obstructive sleep apnea. *Stroke*. 1996;27(3):401–407. doi:10.1161/01.STR.27.3.401
73. Arzt M, Young T, Finn L, Skatrud JB, Bradley TD. Association of sleep-disordered breathing and the occurrence of stroke. *Am J Respir Crit Care Med*. 2005;172(11):1447–1451. doi:10.1164/rccm.200505-7020C
74. Munoz R, Duran-Cantolla J, Martinez-Vila E, et al. Severe sleep apnea and risk of ischemic stroke in the elderly. *Stroke*. 2006;37(9):2317–2321. doi:10.1161/01.STR.0000236560.15735.0f
75. Marshall NS, Wong KK, Cullen SR, Knuiman MW, Grunstein RR. Sleep apnea and 20-year follow-up for all-cause mortality, stroke, and cancer incidence and mortality in the Busselton health study cohort. *J Clin Sleep Med*. 2014;10(4):355–362. doi:10.5664/jcsm.3600